Close

GlaxoSmithKline (GSK) Receives FDA Approval for Expanded FluLaval Quadrivalent Indication

Go back to GlaxoSmithKline (GSK) Receives FDA Approval for Expanded FluLaval Quadrivalent Indication

GSK receives FDA approval for expanded indication for FluLavalĀ® Quadrivalent (Influenza Vaccine) for infants 6 months and older

November 21, 2016 8:28 AM EST

PHILADELPHIA, Nov. 21, 2016 /PRNewswire/ -- GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding the indication for FluLaval® Quadrivalent (Influenza Vaccine) to include use in children 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older.

"The flu is a serious disease with a significant impact on public health and can lead to thousands of deaths in the US every flu... More